Anvisa bans sales of irregular medicines in Brazil
The bans cover insulin distributed without authorization, an improperly compounded product and unregistered peptides, as well as two medicine batches with quality issues.
Event / data period: 2026-10-06
Published: · Updated:
Brazil’s health regulator Anvisa banned the sale of several irregular medicines on October 6. The measures cover insulin glargine distributed by a company without authorization, a compounded medicine marketed to the public without prescriptions, and unregistered peptides.
Anvisa also reported a manufacturer’s voluntary recall of one Imaavy batch and ordered a recall of one Lizbi antibiotic batch after confirming loss of sterility linked to compromised packaging. This account reports regulatory actions and is not individual treatment advice.
Data
Medicines prohibited or recalled
Products and action types in Anvisa’s October 6, 2026 notice.
| Insulin glargine 3 mL/100 IU, Costa Mar | Sale of all lots prohibited; distributor lacked authorization. |
| Vermefree compounded medicine, Sintonia Pharma | Sale, distribution and advertising prohibited; regulator cited standardized non-individualized compounding marketed without prescription. |
| Unregistered peptides listed in notice | Sale, manufacture, distribution, advertising, transport and use prohibited. |
| Imaavy batch JNYJ1201 | Voluntary recall reported; possible glass particles in vials. |
| Lizbi batch 0000207107 | Recall ordered after confirmed sterility loss linked to compromised primary packaging. |
Methodology
The table summarizes the scope of the notice in the source’s terms; it does not provide medical guidance.
Updated:
Subjects and places
Subject proposals
- HealthSuggested
- Preserved editorial category/topic; broad candidate onlywww.gov.br ↗
Geographic references
Only source-provided geographic references are shown. Opening an external map is optional. Optional story maps use OpenStreetMap. Opening a map sends your IP address and this site’s address to the map provider; location data remains readable as text without loading the map.
- Brazil · Place role: Coverage · Place type: Country or area · Location precision: RegionalEvidence
- Explicit preserved editorial country/region; no city or national centroid inferredwww.gov.br ↗